Literature DB >> 25942429

TLR2 and TLR4 expression on CD14(++) and CD14(+) monocyte subtypes in adult-onset autoimmune diabetes.

Pavlina Cejkova1,2, Iva Nemeckova1, Jan Broz3, Marie Cerna2.   

Abstract

BACKGROUND: Peripheral blood monocytes are key effectors of innate immunity. Dysfunction, changes in their counts or altered expression of cytokines and pattern-recognition receptors on monocytes may contribute to the development of the autoimmune type of diabetes mellitus (AD). AIMS: We aimed to analyze the counts and proportions of the two main subtypes of monocyte cells, CD14(++) and CD14(+), and to look for potential changes in the expression of toll-like receptors 2 (TLR2) and 4 (TLR4) as well as cytokine prolactin (PRL) in adult-onset AD, including diabetes mellitus type 1 (T1DM) and latent autoimmune diabetes in adults (LADA).
METHODS: We examined 21 T1DM patients, 9 patients with LADA, 16 control patients with type 2 diabetes mellitus (T2DM) and 24 healthy individuals. All diabetic patients were diagnosed after the age of 18 years. Expression at the mRNA level was determined by quantitative PCR. Flow cytometry was used to ascertain membrane expression and cell counts.
RESULTS: T1DM patients had fewer CD14(++) (P < 0.01) and CD14(+) (P < 0.0001) monocytes whereas T2DM subjects showed decreased counts of CD14(+) monocytes compared to healthy controls (P < 0.001). TLR2 protein expression was significantly increased in T1DM CD14(+) monocytes compared to healthy controls (P < 0.05), while TLR4 expression in T1DM CD14(++) cells was significantly lower (P < 0.0001). There was no significant difference between the groups in terms of PRL mRNA expression in monocytes.
CONCLUSIONS: The observed changes in the proportions of both immune cell types and in the expression of functional pattern-recognition receptors on monocytes in the subjects examined may arise as a consequence of chronic inflammation that accompanies long-term diabetes.

Entities:  

Keywords:  CD14 monocyte; adult-onset autoimmune diabetes; inflammation; prolactin; toll-like receptor

Mesh:

Substances:

Year:  2015        PMID: 25942429     DOI: 10.5507/bp.2015.016

Source DB:  PubMed          Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub        ISSN: 1213-8118            Impact factor:   1.245


  6 in total

Review 1.  Innate immunity in latent autoimmune diabetes in adults.

Authors:  Juan Huang; James Alexander Pearson; F Susan Wong; Li Wen; Zhiguang Zhou
Journal:  Diabetes Metab Res Rev       Date:  2021-06-22       Impact factor: 4.876

2.  Prevalence of pulmonary tuberculosis in young adult patients with Type 1 diabetes mellitus in India.

Authors:  Abilash Nair; Randeep Guleria; Devasenathipathy Kandasamy; Raju Sharma; Nikhil Tandon; Urvashi B Singh; Ravinder Goswami
Journal:  Multidiscip Respir Med       Date:  2016-05-10

Review 3.  Latent Autoimmune Diabetes in Adults (LADA): From Immunopathogenesis to Immunotherapy.

Authors:  Jingyi Hu; Rong Zhang; Hailan Zou; Lingxiang Xie; Zhiguang Zhou; Yang Xiao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-21       Impact factor: 6.055

Review 4.  Latent autoimmune diabetes in adults in China.

Authors:  Junlin Qiu; Zilin Xiao; Ziwei Zhang; Shuoming Luo; Zhiguang Zhou
Journal:  Front Immunol       Date:  2022-08-25       Impact factor: 8.786

5.  Differential Expression of Human Peripheral Mononuclear Cells Phenotype Markers in Type 2 Diabetic Patients and Type 2 Diabetic Patients on Metformin.

Authors:  Mohammed S Al Dubayee; Hind Alayed; Rana Almansour; Nora Alqaoud; Rahaf Alnamlah; Dana Obeid; Awad Alshahrani; Mahmoud M Zahra; Amre Nasr; Ahmad Al-Bawab; Ahmad Aljada
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-09       Impact factor: 5.555

6.  Fucoidan prevent murine autoimmune diabetes via suppression TLR4-signaling pathways, regulation DC/Treg induced immune tolerance and improving gut microecology.

Authors:  Meilan Xue; Hui Liang; Xinqiang Ji; Ying Liu; Yinlin Ge; Lin Hou; Ting Sun
Journal:  Nutr Metab (Lond)       Date:  2019-12-16       Impact factor: 4.169

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.